In addition, patients who were classified as non-responders to a 24-week treatment of etanercept were noted to have lower baseline IL-12 serum levels than the responders, hence may be suggestive of IL-12 as a potential biomarker or predictor for clinical response to etanercept, which is a TNF-inhibitor used to treat psoriasis (Lu et al., 2016). The gene discussed is TNF; the disease is psoriasis.